XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Segments (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting, Asset Reconciling Item [Line Items]    
Number of reportable segments | segment 1  
Research and development expenses:    
Research and development expenses $ 2,189 $ 2,815
General and administrative expenses:    
Stock-based compensation 435 1,155
General and administrative expenses 1,205 1,928
Loss from operations (3,394) (4,743)
Net loss (3,347) (4,603)
Reportable Segment    
Research and development expenses:    
Clinical trial expenses 1,659 1,575
Contract manufacturing 24 214
Salaries and benefits related 329 394
Consulting & Other 17 66
Stock-based compensation 160 566
Research and development expenses 2,189 2,815
General and administrative expenses:    
Salaries and benefits related 230 324
Legal fees 167 257
Audit fees 77 115
Consulting 196 173
Insurance 157 286
Other 103 184
Stock-based compensation 275 589
General and administrative expenses 1,205 1,928
Loss from operations (3,394) (4,743)
Other segment items 47 140
Net loss (3,347) (4,603)
IT-01 Study (Phase 1/2 Metastatic Cancers) | Reportable Segment    
Research and development expenses:    
Clinical trial expenses 0 53
INVINCIBLE-2 Study (Phase 2 Breast) | Reportable Segment    
Research and development expenses:    
Clinical trial expenses 0 103
INVINCIBLE-3 Study (Phase 3 Sarcoma) | Reportable Segment    
Research and development expenses:    
Clinical trial expenses 1,596 1,419
INVINCIBLE-4 Study (Phase 2 Breast) | Reportable Segment    
Research and development expenses:    
Clinical trial expenses $ 63 $ 0